Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.

Leukemia & lymphoma - 1 Jan 2015

Rajić Vladan, Debeljak Maruša, Goričar Katja, Jazbec Janez

Abstract excerpt

l-asparaginase is an effective antineoplastic agent used in chemotherapy of acute lymphoblastic leukemia. The drug effect may be compromised by an elicited immune response, resulting in the production of anti-asparaginase antibodies causing an anaphylactic reaction or silent inactivation of the enzyme. To elucidate possible genetic predisposition for inter-individual differences in asparaginase hypersensitivity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asparaginase

Share to Cohort Studies

Share to Drug Hypersensitivity

Share to Odds Ratio

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Receptors, AMPA

Source

Identifiers

PMID: 25697915
DOI: 10.3109/10428194.2015.1020802

Genes

GRIA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.PMID 25697915Read ↗

Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.Semantic proximity Read ↗

Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.Semantic proximity Read ↗

Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.Semantic proximity Read ↗

HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Semantic proximity Read ↗

Pharmacogenetic markers of PEG-asparaginase toxicity in Brazilian pediatric ALL: insights from a multicenter prospective cohort study.Semantic proximity Read ↗

Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.Semantic proximity Read ↗

HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity.Semantic proximity Read ↗

HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemiaSemantic proximity Read ↗

Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.Semantic proximity Read ↗

Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Update on the Use of L-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.